Full List Of Stories
Broker tips: Rotork, Trustpilot
JPMorgan Cazenove upgraded Rotork on Wednesday to 'overweight' from 'neutral' and lifted its price target on the stock to 370. 0p from 365. 0p.
Director dealings: Jet2 founder lowers stake
Jet2 revealed on Wednesday that Philip Meeson had disposed of 5. 0m ordinary shares in the London-listed leisure travel business.
US open: Stocks sharply lower following August CPI report
Wall Street stocks were firmly in the early on Wednesday as market participants digested last month's consumer inflation report.
Berenberg slightly raises target price on Trustpilot
Analysts at Berenberg slightly raised their target price on reviews platform operator Trustpilot from 260. 0p to 270. 0p on Wednesday following the group's interim results earlier in the morning.
US pre-open: Futures lower ahead of August CPI reading
Wall Street futures were in the red ahead of the bell on Wednesday as market participants prepped for last month's consumer inflation report.
Abu Dhabi National Oil expected to make formal offer for Covestro
Abu Dhabi National Oil Company was expected to make a formal offer to acquire German plastic and chemicals manufacturer Covestro for approximately €14. 4bn including debt, according to the Financial Times.
Anglo American raises ZAR 7.2bn via accelerated bookbuild
Mining giant Anglo American has raised ZAR 7. 2bn (£308. 03m) after an accelerated bookbuild saw it offer up 13. 94m ordinary shares at a price of ZAR 515. 0p per share.
Heathrow sets new monthly record for passenger numbers in August
British airport Heathrow said on Wednesday that it had set a new monthly record for passenger numbers in August, with 7. 97m people passing through its gates last month.
Firstgroup names Lena Wilson as chair
Public transport business Firstgroup has tapped Lena Wilson to take over as chair, with effect from 1 February 2025.
GSK's herpes vaccine candidate fails to meet primary efficacy objective
Drugmaker GSK said on Wednesday that primary objective data analysts from a phase II trial of its early-stage therapeutic herpes simplex virus vaccine candidate showed that the drug had failed to meet its primary efficacy objective.